Table of Contents

Definition of Phencyclidine Use Disorder

Phencyclidine Use Disorder, commonly known as PCP Use Disorder, refers to a condition characterized by a pattern of problematic use of phencyclidine, a dissociative drug that alters perception, mood, and behavior. This disorder falls under the category of substance use disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Individuals with Phencyclidine Use Disorder display symptoms such as:

  • Compulsive drug-seeking behavior: Spending a significant amount of time obtaining, using, or recovering from the effects of PCP.
  • Loss of control: Difficulty in controlling or limiting PCP use, despite being aware of its negative consequences.
  • Continued use despite harm: Persistent use of PCP despite experiencing physical, psychological, social, or other adverse effects.
  • Tolerance: Needing larger doses of PCP over time to achieve the desired effects.
  • Withdrawal symptoms: Experiencing withdrawal symptoms when not using PCP, which can include depression, anxiety, sweating, and cravings.

The diagnosis of Phencyclidine Use Disorder is typically made by a healthcare professional based on specific criteria outlined in the DSM-5. Treatment for this disorder often involves a combination of behavioral therapies, counseling, support groups, and, in some cases, medications to manage withdrawal symptoms or address co-occurring mental health conditions.

History of Phencyclidine Use Disorder

Phencyclidine, commonly known as PCP, emerged in the 1950s as an intravenous anesthetic pharmaceutical. Initially used in medical settings, it was later discontinued due to its severe side effects, including agitation, hallucinations, and delirium, which could last for days.

Here’s a brief history of Phencyclidine Use Disorder:

Medical Use:

PCP was initially developed as an anesthetic agent and was used in medicine in the 1950s and 1960s. However, due to its unpredictable and adverse side effects on patients, including agitation, hallucinations, and erratic behavior, its medical use was discontinued in the 1960s.

Recreational Use:

Despite its discontinuation in medical settings, PCP became popular as a recreational drug in the 1960s and 1970s due to its hallucinogenic and dissociative effects. It was available in various forms, such as pills, capsules, and powder, and was often smoked, snorted, or ingested.

Regulation and Decline in Use:

As reports of PCP-related emergency room visits and incidents of unpredictable and violent behavior increased, the drug was classified as a Schedule II controlled substance in the United States in 1978. This classification significantly restricted its production, distribution, and use. As a result, PCP use declined in subsequent years.

Current Status:

Although its prevalence has diminished compared to its peak in the 1970s and 1980s, PCP continues to be used illicitly in some regions. It’s considered a dangerous drug due to its unpredictable effects, potential for addiction, and associated health risks.

Phencyclidine Use Disorder, as recognized in the DSM-5, describes a pattern of problematic PCP use leading to significant impairment or distress in various areas of life. Treatment typically involves a combination of behavioral therapies, counseling, and support groups to help individuals overcome addiction and manage associated problems.

DSM-5 criteria of Phencyclidine Use Disorder

Phencyclidine Use Disorder, as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is a clinical diagnosis characterized by a problematic pattern of phencyclidine (PCP) use leading to significant impairment or distress. The criteria for diagnosing Phencyclidine Use Disorder include:

A. Impaired Control: The individual displays difficulty in controlling PCP use, such as consuming larger amounts or for a longer duration than intended, unsuccessful attempts to cut down or control use, spending excessive time obtaining, using, or recovering from the drug, and strong cravings.

B. Social Impairment: The continued use of PCP leads to significant problems in various areas of life. This may include persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of PCP, failure to fulfill major obligations at work, school, or home due to PCP use, and giving up important social, occupational, or recreational activities due to PCP use.

C. Risky Use: The individual continues to use PCP despite being aware of the physical or psychological problems it causes or worsens. This can manifest as the use of PCP in situations where it is physically hazardous, such as while driving or operating machinery.

D. Pharmacological Criteria: The presence of tolerance, wherein increased amounts of PCP are needed to achieve the desired effect, and the development of withdrawal symptoms when PCP use is reduced or ceased. Withdrawal symptoms associated with PCP use may include depression, anxiety, irritability, and cravings.

E. Duration: These symptoms persist for a significant period, typically at least 12 months, leading to clinically significant distress or impairment in social, occupational, or other important areas of functioning.

The severity of Phencyclidine Use Disorder is classified as mild, moderate, or severe based on the number of criteria met:

  • Mild: Presence of 2-3 symptoms.
  • Moderate: Presence of 4-5 symptoms.
  • Severe: Presence of 6 or more symptoms.

It’s essential to note that a diagnosis should be made by a qualified healthcare professional or mental health provider based on a comprehensive assessment considering all relevant factors and using the DSM-5 criteria as a guide.

Etiology of Phencyclidine Use Disorder

The development of Phencyclidine Use Disorder, like other substance use disorders, is influenced by a combination of various factors, including biological, psychological, social, and environmental elements. Here are some key factors contributing to the etiology of Phencyclidine Use Disorder:

Biological Factors:

Genetic predisposition and individual differences in brain chemistry can play a role in susceptibility to substance use disorders, including Phencyclidine Use Disorder. Some individuals may have a higher genetic vulnerability to addiction, which can be influenced by family history and genetic variations related to the brain’s reward system.

Psychological Factors:

Co-occurring mental health conditions like depression, anxiety disorders, trauma-related disorders, or personality disorders can contribute to the development of substance use disorders. Individuals may use PCP as a way to self-medicate or cope with underlying psychological issues.

Social and Environmental Factors:

Environmental influences, such as exposure to stress, trauma, peer pressure, dysfunctional family dynamics, poverty, lack of social support, or easy access to drugs, can significantly impact the initiation and maintenance of PCP use.

Developmental Factors:

Early exposure to substances, childhood trauma, neglect, or abuse can increase the likelihood of developing substance use disorders later in life. Moreover, certain developmental stages, such as adolescence, are associated with increased experimentation and susceptibility to drug use due to changes in brain development and social influences.

Behavioral Reinforcement:

The rewarding effects of PCP, such as euphoria or dissociation from reality, can reinforce continued use. Positive experiences with the drug may contribute to repeated use, leading to the development of tolerance and dependence.

Neurobiological Mechanisms:

PCP acts on various neurotransmitter systems in the brain, particularly the glutamate system. Its interactions with NMDA receptors affect neural communication and contribute to its psychoactive effects. These neurobiological changes can influence addictive behaviors and contribute to the development of dependence.

Understanding these multifaceted factors is crucial for prevention, early intervention, and treatment strategies for Phencyclidine Use Disorder. Comprehensive approaches that address biological, psychological, social, and environmental aspects are essential in effectively managing and treating substance use disorders, including PCP addiction. Treatment often involves a combination of behavioral therapies, counseling, support groups, and sometimes medication-assisted treatment.

Theories related to Phencyclidine Use Disorder

Several theories have been proposed to explain the development, maintenance, and treatment of Phencyclidine Use Disorder (PCP addiction). These theories offer insights into the various aspects of addiction and its complexities. Some relevant theories include:

Biological and Genetic Theories:

These theories emphasize the role of genetics, neurobiology, and pharmacology in addiction. Genetic predisposition and variations in brain chemistry can influence an individual’s vulnerability to PCP addiction. The interaction between PCP and neurotransmitter systems, particularly the glutamate system and NMDA receptors, contributes to its addictive properties.

Reward Pathway and Reinforcement Theories:

Addiction theories often focus on the brain’s reward pathway, involving neurotransmitters like dopamine, which plays a key role in reinforcement and motivation. The rewarding effects of PCP, such as euphoria and altered perceptions, reinforce continued use, leading to addiction.

Psychological Theories:

Psychological theories highlight the influence of psychological factors in addiction. These include stress, trauma, mental health conditions, personality traits, and coping mechanisms. For instance, individuals might use PCP as a way to cope with stress or trauma, leading to dependence.

Social Learning and Environmental Theories:

These theories emphasize the impact of social and environmental factors on addiction. Exposure to peers who use drugs, family dynamics, socioeconomic status, access to drugs, and societal attitudes toward drug use can all contribute to the initiation and maintenance of PCP addiction.

Cognitive-Behavioral Theories:

These theories focus on how thoughts, behaviors, and beliefs contribute to addiction. Cognitive processes, such as rationalization, denial, and distorted thinking patterns about drug use, can perpetuate addictive behaviors. Behavioral patterns related to seeking and using PCP are also central to these theories.

Dual Diagnosis and Comorbidity Theories:

These theories recognize the high prevalence of co-occurring mental health conditions (dual diagnosis) with substance use disorders. They emphasize the bidirectional relationship between addiction and mental health issues, suggesting that treating both conditions simultaneously is essential for successful recovery.

Neuroplasticity and Craving Theories:

These theories focus on the brain’s ability to adapt and change (neuroplasticity) in response to drug use. They suggest that prolonged drug use alters brain circuits, leading to heightened craving and a reduced ability to control drug-seeking behaviors.

Understanding these theories helps clinicians, researchers, and policymakers develop more comprehensive and effective strategies for preventing, treating, and managing Phencyclidine Use Disorder. Treatment approaches often incorporate elements from multiple theories to address the multifaceted nature of addiction. This might include behavioral therapies, medications, support groups, and holistic approaches aimed at addressing biological, psychological, and social aspects of addiction.

Risk factors of Phencyclidine Use Disorder

Several risk factors contribute to the development of Phencyclidine Use Disorder (PCP addiction). These factors can vary from individual to individual and interact in complex ways. Some common risk factors include:

Genetics and Family History:

Genetic predisposition plays a role in susceptibility to addiction. Individuals with a family history of substance use disorders may have a higher risk of developing PCP addiction due to inherited genetic factors.

Biological Factors:

Certain biological factors, such as differences in brain chemistry, neurobiological vulnerabilities, and alterations in neurotransmitter systems, can increase the likelihood of addiction.

Mental Health Conditions:

Co-occurring mental health disorders, such as depression, anxiety, bipolar disorder, schizophrenia, or personality disorders, can contribute to the development of PCP addiction. Individuals might use PCP as a way to self-medicate or alleviate symptoms of underlying mental health issues.

Early Exposure and Environment:

Exposure to drugs during early adolescence, peer pressure, availability of drugs in the environment, dysfunctional family dynamics, childhood trauma, neglect, or abuse can significantly increase the risk of substance use disorders, including PCP addiction.

Stress and Trauma:

High levels of stress, traumatic experiences, or adverse life events can increase vulnerability to substance abuse as individuals may turn to drugs like PCP as a coping mechanism.

Socioeconomic Factors:

Socioeconomic status, poverty, lack of access to education or resources, and living in environments with high rates of drug availability or crime can contribute to an increased risk of drug use and addiction.

Personality and Behavioral Traits:

Certain personality traits, such as impulsivity, sensation-seeking behavior, risk-taking tendencies, and a lack of coping skills, can predispose individuals to engage in substance abuse, including PCP use.

Peer Influence and Social Networks:

Influence from peers who use drugs, social acceptance of drug use within certain social circles, and social norms that tolerate or promote substance use can influence an individual’s likelihood of trying and continuing to use PCP.

Access to Drugs:

Easy availability and access to PCP or other drugs increase the likelihood of experimentation and subsequent addiction.

Recognizing these risk factors is crucial for prevention efforts and early intervention strategies. Interventions that address these factors through education, targeted interventions, improving coping skills, providing mental health support, promoting healthier environments, and addressing societal influences can help reduce the risk of Phencyclidine Use Disorder and other substance use disorders.

Treatment for Phencyclidine Use Disorder

Treating Phencyclidine Use Disorder (PCP addiction) typically involves a comprehensive approach that addresses various aspects of addiction, including biological, psychological, social, and environmental factors. Treatment strategies may include:


The first step often involves medically supervised detoxification to manage withdrawal symptoms safely. PCP withdrawal symptoms can include depression, anxiety, irritability, and cravings. Medical professionals may provide supportive care and medications, if necessary, to alleviate these symptoms.

Behavioral Therapies:

Behavioral therapies, such as Cognitive-Behavioral Therapy (CBT), Motivational Interviewing (MI), Contingency Management (CM), and Dialectical Behavior Therapy (DBT), are commonly used in treating PCP addiction. These therapies aim to modify thought patterns, behaviors, and attitudes related to drug use, help individuals develop coping strategies, and improve decision-making skills to avoid relapse.

Individual and Group Counseling:

Counseling sessions, both individual and group-based, provide a supportive environment for individuals to explore the underlying issues contributing to addiction, learn healthier coping mechanisms, and receive guidance on relapse prevention strategies.

Medication-Assisted Treatment (MAT):

Currently, there are no specific medications approved for treating PCP addiction. However, medications may be used to manage co-occurring mental health conditions or to alleviate certain withdrawal symptoms that arise during detoxification.

Dual Diagnosis Treatment:

Many individuals with PCP Use Disorder have co-occurring mental health conditions. Treating both the addiction and any underlying mental health issues concurrently (dual diagnosis treatment) is crucial for comprehensive recovery.

Support Groups:

Participation in support groups, such as Narcotics Anonymous (NA) or SMART Recovery, provides individuals with a supportive community of peers in recovery, offering encouragement, guidance, and shared experiences.

Family Therapy and Support:

Involving family members in therapy sessions can help repair relationships, improve family dynamics, and create a supportive environment for the individual in recovery.

Holistic Approaches:

Holistic therapies, such as mindfulness practices, yoga, exercise, nutritional counseling, and stress reduction techniques, can complement traditional treatments by promoting overall well-being and aiding in stress management.

Aftercare and Relapse Prevention:

Continued support and aftercare programs are essential in maintaining sobriety. These programs may include ongoing therapy, regular check-ins, and relapse prevention strategies to help individuals navigate challenges in the post-treatment phase.

Successful treatment for Phencyclidine Use Disorder often involves a tailored approach that considers the unique needs and circumstances of the individual. It’s crucial for individuals seeking help to engage in a comprehensive treatment program under the guidance of qualified healthcare professionals or addiction specialists.

Therapies for Phencyclidine Use Disorder

Treating Phencyclidine Use Disorder (PCP addiction) involves various therapeutic approaches designed to address the complexity of addiction and aid in recovery. Some effective therapies used in managing PCP Use Disorder include:

Cognitive-Behavioral Therapy (CBT):

CBT helps individuals recognize and modify maladaptive thought patterns and behaviors associated with PCP use. It focuses on identifying triggers, developing coping skills, and altering responses to cravings, leading to healthier decision-making.

Motivational Interviewing (MI):

MI is a client-centered approach that helps individuals explore their ambivalence towards change and enhances their motivation to quit using PCP. It involves eliciting and strengthening intrinsic motivation for change.

Contingency Management (CM):

CM is a behavior therapy that uses positive reinforcement to encourage abstinence from PCP. It involves providing rewards or incentives, such as vouchers or privileges, for meeting treatment goals, such as staying drug-free.

Dialectical Behavior Therapy (DBT):

DBT combines cognitive-behavioral techniques with mindfulness practices. It helps individuals regulate emotions, improve interpersonal skills, manage stress, and cope with triggers that might lead to drug use.

Group Therapy:

Participating in group therapy sessions provides support, encouragement, and a sense of community among individuals facing similar challenges. It allows for shared experiences, learning from peers, and practicing new coping strategies in a supportive environment.

Family Therapy:

Involving family members in therapy sessions can help improve family dynamics, address communication issues, and provide support for both the individual in recovery and their loved ones. It can contribute to a more conducive environment for sustained recovery.

Holistic Therapies:

Holistic approaches such as mindfulness meditation, yoga, art therapy, and acupuncture can complement traditional therapies by promoting relaxation, stress reduction, and overall well-being. These therapies focus on the mind-body connection and can aid in managing triggers and cravings.

Relapse Prevention Techniques:

Therapeutic interventions often involve teaching individuals strategies to recognize and cope with triggers, develop healthy coping mechanisms, and create a personalized relapse prevention plan to maintain sobriety.

These therapeutic approaches can be used individually or in combination based on the individual’s needs, preferences, and the recommendations of healthcare professionals. The effectiveness of therapy often lies in its customization to address the specific challenges and circumstances of each person undergoing treatment for PCP Use Disorder.

Preventions of Phencyclidine Use Disorder

Preventing Phencyclidine Use Disorder (PCP addiction) involves a combination of strategies targeting different levels of influence, including individuals, families, communities, and society. Some key preventive measures include:

Education and Awareness:

Providing accurate and comprehensive information about the risks and dangers associated with PCP use is crucial. Educational campaigns aimed at schools, communities, and healthcare settings can help raise awareness about the harmful effects of PCP and discourage its use.

Early Intervention Programs:

Implementing early intervention programs that focus on identifying and addressing risk factors in adolescents, such as peer pressure, trauma, and poor coping skills, can help prevent initiation of PCP use.

Strengthening Resilience:

Promoting protective factors, such as building strong social support networks, enhancing coping skills, fostering resilience, and improving problem-solving abilities, can reduce the susceptibility to substance abuse, including PCP.

Parental Involvement:

Encouraging positive parenting practices, open communication, and parental involvement in children’s lives can help reduce the risk of substance abuse. Providing parents with guidance on recognizing and addressing risk behaviors in their children can be beneficial.

Community-Based Programs:

Implementing community-based prevention programs, youth development initiatives, after-school activities, and positive alternative activities can provide young individuals with healthy outlets and reduce their inclination toward substance use.

Restricting Access:

Enforcing strict regulations and controls on the availability and distribution of PCP, including its illegal production and sale, can limit access to the drug and reduce its prevalence.

School-Based Prevention:

Introducing substance abuse prevention programs in schools that incorporate evidence-based curricula, life skills training, peer counseling, and education on the consequences of drug use can help prevent PCP experimentation.

Screening and Early Intervention in Healthcare Settings:

Healthcare providers can play a role in identifying individuals at risk of substance abuse during routine screenings and offering early interventions or referrals to specialized treatment when needed.

Media and Public Awareness:

Utilizing media platforms to disseminate accurate information about the dangers of PCP use and promoting positive messaging around healthy lifestyles and substance-free choices can influence public attitudes and behaviors.

Policy and Legislation:

Implementing and enforcing policies and legislation aimed at reducing drug availability, providing treatment resources, and supporting prevention efforts can have a significant impact on reducing PCP use.

Preventing Phencyclidine Use Disorder requires a multifaceted approach involving collaboration between individuals, families, communities, healthcare professionals, educators, policymakers, and various stakeholders. By addressing risk factors and promoting protective factors across different domains, comprehensive prevention efforts can help reduce the incidence of PCP addiction.

author avatar